Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Debt to Equity (2016 - 2022)

Lexaria Bioscience's Debt to Equity history spans 8 years, with the latest figure at $0.0 for Q2 2022.

  • For Q2 2022, Debt to Equity rose 587.8% year-over-year to $0.0; the TTM value through May 2022 reached $0.0, up 587.8%, while the annual FY2021 figure was $0.0, 95.09% down from the prior year.
  • Debt to Equity for Q2 2022 was $0.0 at Lexaria Bioscience, up from $0.0 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.06 in Q4 2020 and bottomed at $0.0 in Q2 2021.
  • The 5-year median for Debt to Equity is $0.0 (2018), against an average of $0.01.
  • The largest annual shift saw Debt to Equity tumbled 99.65% in 2018 before it skyrocketed 2023.81% in 2021.
  • A 5-year view of Debt to Equity shows it stood at $0.01 in 2018, then skyrocketed by 124.29% to $0.01 in 2019, then soared by 355.67% to $0.06 in 2020, then crashed by 99.06% to $0.0 in 2021, then surged by 46.2% to $0.0 in 2022.
  • Per Business Quant, the three most recent readings for LEXX's Debt to Equity are $0.0 (Q2 2022), $0.0 (Q1 2022), and $0.0 (Q3 2021).